Compounds > leflunomide

leflunomide and oseltamivir

leflunomide has been researched along with oseltamivir in 4 studies

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's3 (75.00)24.3611
2020's1 (25.00)2.80

Authors

AuthorsStudies
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Jones, LH; Nadanaciva, S; Rana, P; Will, Y1
Chen, Y; Ding, M; Jiang, X; Lan, K; Lavillete, D; Li, H; Li, S; Liu, Y; Shan, J; Shang, W; Shen, Z; Sun, Y; Tong, Y; Wang, R; Wang, Y; Wu, Y; Xiao, G; Xiong, R; Xu, K; Xu, L; Zhang, L; Zhao, Y; Zhao, Z; Zhu, L; Zou, G1

Reviews

1 review(s) available for leflunomide and oseltamivir

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Other Studies

3 other study(ies) available for leflunomide and oseltamivir

ArticleYear
FDA-approved drug labeling for the study of drug-induced liver injury.
    Drug discovery today, 2011, Volume: 16, Issue:15-16

    Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration

2011
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
    Bioorganic & medicinal chemistry letters, 2016, 08-15, Volume: 26, Issue:16

    Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone

2016
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
    Protein & cell, 2020, Volume: 11, Issue:10

    Topics: Animals; Antiviral Agents; Betacoronavirus; Binding Sites; Cell Line; Coronavirus Infections; COVID-19; Crotonates; Cytokine Release Syndrome; Dihydroorotate Dehydrogenase; Drug Evaluation, Preclinical; Gene Knockout Techniques; Humans; Hydroxybutyrates; Influenza A virus; Leflunomide; Mice; Mice, Inbred BALB C; Nitriles; Orthomyxoviridae Infections; Oseltamivir; Oxidoreductases; Oxidoreductases Acting on CH-CH Group Donors; Pandemics; Pneumonia, Viral; Protein Binding; Pyrimidines; RNA Viruses; SARS-CoV-2; Structure-Activity Relationship; Thiazoles; Toluidines; Ubiquinone; Virus Replication

2020